Drug Combination Details
| General Information of the Combination (ID: C17411) | |||||
|---|---|---|---|---|---|
| Name | Sclareol NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| 4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | |||
| Experimental
Result(s) |
The SLN-DOX-SC demonstrated to be more effective than the free DOX against 4T1 cells. So, the developed SLN efficiently encapsulate DOX and SC and show good potential as an alternative for cancer treatment. | |||||
| β. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| 4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | |||
| In-vivo Model | 4T1 (2.5 * 106 ) tumour cells were subcutaneously injected into the right thigh of female BALB/c mice (5 weeks old, around 20 g). | |||||
| Experimental
Result(s) |
NLC-DOX-SC shows to be a superior option over the free combination as it maintains the synergism between DOX and SC in triple negative breast cancer models and is less toxic (less myelossupressive, prevents weight loss and behaviour alterations) than the free combination, showing the benefits of nanomedicine in reducing chemotherapy side effects. | |||||
